ArticleCureus2025
Immunohistochemical Evaluation of Phosphatase and Tensin Homolog (PTEN) Expression in Endometrial Lesions: A Cross-Sectional Study in a Tertiary Care Center in South India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial carcinoma is a common gynecological malignancy, with type I endometrioid carcinoma often arising from precursor lesions like endometrial hyperplasia. The tumor suppressor gene PTEN (phosphatase and tensin homolog) regulates cell proliferation and apoptosis via inhibition of the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway. Its loss is considered an early molecular event in endometrial carcinogenesis. This study aimed to evaluate the immunohistochemical expression of PTEN across various endometrial lesions and correlate its expression with histopathological subtypes and tumor grade. METHODOLOGY: This cross-sectional study was conducted in the Department of Pathology, Sree Balaji Medical College and Hospital, from July 2023 to June 2025. Fifty cases were included: disordered proliferative endometrium (
resultsPTEN expression was preserved in most benign lesions, with moderate to strong staining in disordered proliferative endometrium and hyperplasia without atypia. Reduced staining was seen in hyperplasia with atypia. Among endometrioid carcinomas, 10/15 (66.7%) showed complete loss of PTEN, and loss correlated with higher histological grade and deeper myometrial invasion. All papillary serous carcinomas showed complete loss of PTEN. The association between PTEN expression and histopathological diagnosis was statistically significant (χ² = 52.38;
conclusionsProgressive loss of PTEN expression from benign to malignant lesions highlights its potential as an early diagnostic and prognostic marker in endometrial carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.